Eudralex Volume 2C Guidance on elements required to support the significant benefit in comparison with existing therapies of a new therapeutic indication in order to benefit from an extended (11 years) marketing protection period (November 2007)

Titel:
Eudralex Volume 2C Guidance on elements required to support the significant benefit in comparison with existing therapies of a new therapeutic indication in order to benefit from an extended (11 years) marketing protection period (November 2007)
Herkunft/Verlag:

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL http://ec.europa.eu/enterprise/index_en.htm

Dokumentenart:
EC Guidance Document
Inhalt:
Diese Richtlinie erläutert in welchem Umfang Nachweise zu erbringen sind, um einen verlängerten Patentschutz aufgrund einer neuen therapeutischen Indikation zu erreichen.

Zurück

GMP Seminare nach Thema